Opko Health Inc (OPK)

[game7alcs]

Opko Health reports disappointing results in late-stage trial of human growth hormone product
By Ciara Linnane
Published: Dec 30, 2016 8:43 a.m. ET

SHARE

Opko Health Inc. OPK, +1.06% said Friday a late-stage trial of a human growth hormone product failed to meet its main goal, but said multiple outliers may have affected the result and pledged to further review the patients. The Phase 3 trial of hGH-CTP, an investigational long-acting human growth hormone product failed to produce a statistical difference from placebo, the company said. The safety profile was consistent with other studies of human growth hormone, however. Opko said it has now started a Phase 3 study of the product in children to measure its efficacy versus daily injections of Genotropin, a prescription therapy for children and adults with growth issues. Shares were halted premarket, but have gained 14% on the year, while the S&P 500 SPX, -0.03% has gained 10%.